|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Tigit結合劑和彼之用途
|
|
PT3356413T
(pt)
|
2015-10-01 |
2022-04-04 |
Potenza Therapeutics Inc |
Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
RU2764548C2
(ru)
|
2016-08-09 |
2022-01-18 |
Кимаб Лимитед |
Анти-icos антитела
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
MX2019006072A
(es)
|
2016-11-30 |
2019-08-14 |
Oncomed Pharm Inc |
Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
|
|
JOP20190203A1
(ar)
*
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
|
JP2020517699A
(ja)
|
2017-04-26 |
2020-06-18 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
ジスルフィド結合の還元を最小限にする抗体製造法
|
|
LT3618863T
(lt)
|
2017-05-01 |
2023-10-10 |
Agenus Inc. |
Anti-tigit antikūnai ir jų panaudojimo būdai
|
|
JP7348072B2
(ja)
|
2017-06-01 |
2023-09-20 |
コンピュジェン リミテッド |
三重併用抗体療法
|
|
WO2018229163A1
(en)
|
2017-06-14 |
2018-12-20 |
King's College London |
Methods of activating v delta 2 negative gamma delta t cells
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
CN111051347B
(zh)
*
|
2017-09-29 |
2021-12-21 |
江苏恒瑞医药股份有限公司 |
Tigit抗体、其抗原结合片段及医药用途
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
WO2019122882A1
(en)
|
2017-12-19 |
2019-06-27 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
SG11202004158QA
(en)
|
2017-12-28 |
2020-06-29 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies and variants thereof against tigit
|
|
CA3084518A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
|
SG11202004521QA
(en)
|
2018-02-06 |
2020-06-29 |
I Mab Biopharma Us Ltd |
Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
|
|
US12077583B2
(en)
|
2018-05-09 |
2024-09-03 |
Nectin Therapeutics Ltd. |
Antibodies specific to human NECTIN4
|
|
CN110737397B
(zh)
*
|
2018-07-20 |
2023-08-11 |
伊姆西Ip控股有限责任公司 |
用于管理存储系统的方法、设备和计算机程序产品
|
|
TWI754157B
(zh)
*
|
2018-07-25 |
2022-02-01 |
大陸商信達生物製藥(蘇州)有限公司 |
抗tigit抗體及其用途
|
|
EP3841123A2
(en)
|
2018-08-23 |
2021-06-30 |
Seagen Inc. |
Anti-tigit antibodies
|
|
WO2020127377A1
(en)
|
2018-12-21 |
2020-06-25 |
Ose Immunotherapeutics |
Bifunctional anti-pd-1/il-7 molecule
|
|
EP3908372A1
(en)
|
2019-01-13 |
2021-11-17 |
Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. |
Antibodies specific to human nectin-2
|
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
|
CN111744013B
(zh)
*
|
2019-03-29 |
2022-07-26 |
江苏恒瑞医药股份有限公司 |
抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
|
|
CA3146986A1
(en)
*
|
2019-07-15 |
2021-01-21 |
Shanghai Junshi Biosciences Co., Ltd. |
Anti-tigit antibodies and application thereof
|
|
WO2021093849A1
(en)
*
|
2019-11-14 |
2021-05-20 |
Wuxi Biologics (Shanghai) Co., Ltd. |
A novel antibody against tigit
|
|
TW202136287A
(zh)
|
2019-12-17 |
2021-10-01 |
法商Ose免疫治療公司 |
包含il-7變體之雙官能分子
|
|
CN110818795B
(zh)
*
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
GB202002581D0
(en)
|
2020-02-24 |
2020-04-08 |
Gammadelta Therapeutics Ltd |
Novel antibodies
|
|
EP4147053B1
(en)
|
2020-05-07 |
2026-01-28 |
Institut Curie |
Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
|
|
CN111995681B
(zh)
*
|
2020-05-09 |
2022-03-08 |
华博生物医药技术(上海)有限公司 |
抗tigit的抗体、其制备方法和应用
|
|
WO2021257124A1
(en)
|
2020-06-18 |
2021-12-23 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
|
TW202216778A
(zh)
|
2020-07-15 |
2022-05-01 |
美商安進公司 |
Tigit及cd112r阻斷
|
|
ES2943063T5
(en)
*
|
2020-08-14 |
2026-05-05 |
Gammadelta Therapeutics Ltd |
Multispecific anti-tcr delta variable 1 antibodies
|
|
WO2022044010A1
(en)
|
2020-08-26 |
2022-03-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
|
|
JP7840537B2
(ja)
*
|
2020-10-09 |
2026-04-06 |
慶應義塾 |
免疫・炎症性疾患の治療薬
|
|
US20240002500A1
(en)
*
|
2020-11-23 |
2024-01-04 |
Guangdong Fapon Biopharma Inc. |
Anti-TIGIT Antibody or Antigen-Binding Fragment Thereof
|
|
WO2022112198A1
(en)
|
2020-11-24 |
2022-06-02 |
Worldwide Innovative Network |
Method to select the optimal immune checkpoint therapies
|
|
WO2022148781A1
(en)
|
2021-01-05 |
2022-07-14 |
Institut Curie |
Combination of mcoln activators and immune checkpoint inhibitors
|
|
KR20230159823A
(ko)
|
2021-02-11 |
2023-11-22 |
넥틴 테라퓨틱스 리미티드 |
Cd112r에 대한 항체 및 이의 용도
|
|
KR20230160253A
(ko)
|
2021-02-17 |
2023-11-23 |
감마델타 테라퓨틱스 엘티디 |
항-tcr 델타 가변 1 항체
|
|
EP4320156A1
(en)
|
2021-04-09 |
2024-02-14 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
|
MX2023011964A
(es)
|
2021-04-09 |
2024-01-08 |
Ose Immunotherapeutics |
Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
|
|
AR125753A1
(es)
|
2021-05-04 |
2023-08-09 |
Agenus Inc |
Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
|
|
CA3217279A1
(en)
|
2021-05-04 |
2022-11-10 |
Olga Ignatovich |
Anti-tigit antibodies and methods of use thereof
|
|
US12558406B2
(en)
|
2021-05-10 |
2026-02-24 |
Medimabbio Inc. |
Anti-TIGIT antibodies and use thereof
|
|
CN118871463A
(zh)
|
2021-07-28 |
2024-10-29 |
基因泰克公司 |
用于治疗癌症的方法和组合物
|
|
MX2024001877A
(es)
|
2021-08-10 |
2024-02-28 |
Kymab Ltd |
Tratamiento de dermatitis atopica.
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
CN118119847A
(zh)
*
|
2021-10-08 |
2024-05-31 |
泰贝乐医疗科技有限公司 |
用于检测cdh17的方法和组合物
|
|
CA3243763A1
(en)
|
2022-02-28 |
2023-08-31 |
Nectin Therapeutics Ltd. |
Humanized antibodies directed against nectin-2 and their drug conjugates
|
|
CA3259975A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
|
JP2025523387A
(ja)
|
2022-06-07 |
2025-07-23 |
ジェネンテック, インコーポレイテッド |
抗pd-l1アンタゴニストおよび抗tigitアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
|
|
WO2024003360A1
(en)
|
2022-07-01 |
2024-01-04 |
Institut Curie |
Biomarkers and uses thereof for the treatment of neuroblastoma
|
|
EP4565610A1
(en)
|
2022-08-02 |
2025-06-11 |
Ose Immunotherapeutics |
Multifunctional molecule directed against cd28
|
|
WO2024200820A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Method of synthesis of targeted lipid nanoparticle and uses thereof
|
|
JP2026512425A
(ja)
|
2023-03-30 |
2026-04-16 |
オーエスイー・イミュノセラピューティクス |
免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Il—18bp拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
WO2025068452A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025068461A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025132831A1
(en)
|
2023-12-19 |
2025-06-26 |
Universite D'aix-Marseille |
N-heteroaryl derivatives and uses thereof for treating cancer
|
|
WO2025242835A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of cancer
|
|
WO2025242836A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
|
|
WO2025262250A1
(en)
|
2024-06-20 |
2025-12-26 |
Negio Therapeutics |
Guanfacine derivatives and their uses
|
|
WO2026068705A1
(en)
|
2024-09-26 |
2026-04-02 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof
|